# About GHK-Cu Legal — Independent editorial reading notes on regulatory status > GHK-Cu Legal is an independent editorial project that publishes plain-language, source-cited reading notes on the regulatory status of copper tripeptide-1. We are not a law firm. We do not sell any product. GHK-Cu Legal is an independent editorial project that summarizes the regulatory record for copper tripeptide-1. We are not a law firm, not a clinic, and not affiliated with any manufacturer. Our work is editorial commentary on publicly available regulatory documents. ## What this site is GHK-Cu Legal is an independent editorial project that publishes plain-language summaries of the publicly available regulatory record on GHK-Cu — copper tripeptide-1 — across the FDA bulks lists, the FD&C Act and MoCRA, the EU Cosmetic Products Regulation and the CosIng database, the UK post-Brexit cosmetic framework, the WADA Prohibited List, and the Cosmetic Ingredient Review's 2018 safety determination. The regulatory record on this compound is unusually scattered. The FDA's position on injectable compounding sits in interim 503A bulks list memos and PCAC meeting materials. The EU position sits in a CosIng database entry and the safety dossiers Responsible Persons file under Regulation 1223/2009. The athletic position sits in an annually updated WADA PDF. The cosmetic safety record sits in a 2018 CIR final report. None of these documents is hard to find on its own, but reading them together — and noting where one document's framework qualifies another's — is editorial work that does not exist as a single artifact anywhere we could find. So we wrote it. What we do: read the primary documents, summarize what they say in clear English, link to the live agency URL next to every regulatory claim, and date-stamp every callout so a reader knows when the citation was last verified. The circular 'PRIMARY SOURCE' badges on every regulatory callout link to the live regulator page — they are the visible commitment that this site has been read against the source documents and not just synthesized from secondary commentary. ## What this site is not We are not a law firm. We do not employ attorneys. We do not provide legal advice, regulatory consulting, compliance guidance, or representation. The word 'legal' in the domain name describes the **subject matter** — the regulatory status of GHK-Cu — not a professional service offered by the publisher. There is a long tradition of editorial publications writing about law (court reporters, legal trade press, regulatory newsletters) without being law firms themselves; GHK-Cu Legal sits in that editorial tradition. We are not a clinic. We do not employ physicians, pharmacists, or any clinical staff. We do not provide medical advice and we do not treat any condition. We are not a regulator. Nothing on this site changes the legal status of any compound, product, or claim. Every regulatory statement on the site should be independently verified against primary agency sources before any commercial, clinical, or competitive reliance. For decisions that affect your business or your health, consult a licensed attorney, a regulatory specialist, or a physician — not an editorial reading-notes website. ## Editorial standards and sourcing Every quantitative claim on the site cites a published source. Research-literature citations point to PubMed, PMC, or the publisher; primary-source regulator citations point to the live FDA, EMA, EU CosIng, WADA, or CIR page. Where a status is contested or moving — as with injectable GHK-Cu's 503A bulks list status — we say so in the text, mark the callout as 'STATUS · DISPUTED' or 'STATUS · NOT-LEGAL-ADVICE,' and link the live agency page so the reader can check the current position themselves. We do not paraphrase regulatory language in ways that change its meaning. Where the FDA writes 'does not intend to take enforcement action,' we do not collapse that into 'legal' — those are different things. Where the WADA Prohibited List names categories rather than specific substances, we say the substance is not explicitly named and that 'similar substances' language may apply rather than declaring it 'allowed.' Precision in regulatory writing is the entire trust signal; we try to honor it. Reader corrections are welcome through the [contact page](/contact). --- An independent editorial digest of the published regulatory and research record on GHK-Cu — not legal advice, not medical guidance, not a vendor.